Table 4

Sequential WOMAC A Scores – Pain

Group

Baseline

Week 1

Week 2

Week 4

Week 6

Week 8

Placebo

8.7 ± 1.0

8.9 ± 1.1

8.5 ± 1.2

8.4 ± 1.2

6.8 ± 1.1 *

6.3 ± 1.2 *

A

9.1 ± 1.2

8.1 ± 1.2 *

7.5 ± 1.2 **

6.5 ± 1.2 **

6.4 ± 1.2 **

6.3 ± 1.1 **

B

8.0 ± 1.1

7.5 ± 1.1

6.9 ± 1.1 **

5.7 ± 1.0 **

5.6 ± 1.1 **

5.0 ± 0.9 **

C

8.7 ± 1.0

8.0 ± 1.0b

6.9 ± 0.9 ***

5.6 ± 0.8 ***

5.0 ± 0.8 ***

4.3 ± 0.7 ***

Data expressed as mean ± sem. Group A = High dose sierrasil (n = 20), Group B = Low dose sierrasil (n = 21), Group C = Low dose sierrasil + cat's claw extract (n = 25), placebo n = 22. All groups displayed a significant change over the 8 weeks of the study (p < 0.001, ANOVA). Using the Wilcoxan Matched-Pairs Signed-Rank test the following descriptors reflect statistical significance from baseline; * p < 0.05, ** p < 0.01, *** p < 0.001.

Miller et al. Journal of Inflammation 2005 2:11   doi:10.1186/1476-9255-2-11